Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30262408 | 0.96 | CA1 (0.41) | CA1CA2CA7CA13 | |
| SCHEMBL30262409 | 0.96 | CA1 (0.41) | CA1CA2CA7CA13 | |
| SCHEMBL6031301 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL31279954 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL31721030 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL432957 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| Potassium Ion SCHEMBL878391 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL31268125 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL300203 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL4559812 | 0.93 | CA1 (0.39) | CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079806-A | Method for preparing chiral benzhydrol compound by rhodium-catalyzed asymmetric hydrogenation of o-amidobenzophenone and application of chiral benzhydrol compound | — | 2026-05-26 | — | — | CN | claimed |
| EP-4706123-A2 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | Feon Energy, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024226580-A9 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | FEON ENERGY, INC. (US) | 2025-03-27 | — | — | WO | claimed |
| CN-119409635-A | Fluoro methyl substituted indeno [1,2-b ] pyridine compound with anticancer activity and synthesis method thereof | 河南师范大学 | 2025-02-11 | — | — | CN | claimed |
| CN-119306684-A | Key intermediate for preparing SGLTs inhibitor and preparation method thereof | 宜昌东阳光长江药业股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-119264121-A | Method for activating Michael addition reaction by hydrocarbon bond of heterocyclic carboxylic acid | 齐齐哈尔大学 | 2025-01-07 | — | — | CN | claimed |
| US-20240400559-A1 | SOLID STATE EMITTERS BASED ON PYRIDINIUM SCAFFOLDS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-12-05 | — | — | US | claimed |
| CN-116655567-B | Method for synthesizing 2, 3-disubstituted benzofuran derivatives | 常州大学 | 2024-11-19 | — | — | CN | claimed |
| WO-2024226580-A2 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | FEON ENERGY, INC. (US) | 2024-10-31 | — | — | WO | claimed |
| US-20240360062-A1 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | FEON ENERGY, INC. | 2024-10-31 | — | — | US | claimed |
| CN-114644554-A | Preparation method of (S) -flurbiprofen and intermediate thereof | 上海医药工业研究院 | 2022-06-21 | — | — | CN | claimed |
| CN-114591297-A | Tryptophan-containing polypeptide maleimide derivative and preparation method and application thereof | 浙江工业大学 | 2022-06-07 | — | — | CN | claimed |
| CN-111217731-B | Ortho-imine ester or cyano-substituted aryl thioether derivative, preparation and application thereof | 广东工业大学 | 2022-06-03 | — | — | CN | claimed |
| US-20220168717-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | INSTITUTE FOR BASIC SCIENCE (KR) | 2022-06-02 | — | — | US | claimed |
| CN-114437103-A | Method for synthesizing chiral tetrahydrobenzoxepin compound through gold-catalyzed asymmetric cycloaddition reaction | 山东大学 | 2022-05-06 | — | — | CN | claimed |
| CN-110305156-B | Alkyne derivative containing nitrogen-oxygen bond and preparation method and application thereof | 广东工业大学 | 2022-04-19 | — | — | CN | claimed |
| CN-110305155-B | Alkynyl-containing imine derivative and preparation method and application thereof | 广东工业大学 | 2022-04-19 | — | — | CN | claimed |
| CN-114262290-A | 4-methylene pyrrolidine-2-thioketone compound and synthesis method and application thereof | 华东师范大学 | 2022-04-01 | — | — | CN | claimed |
| CN-114262308-A | 2-methylene-2, 3-dihydrothiazole compounds and synthesis method and application thereof | 华东师范大学 | 2022-04-01 | — | — | CN | claimed |
| CN-114213431-A | Spiro [ benzo [ d ] [1,3] oxazine-isoquinoline dione ] compound and synthetic method thereof | 河南师范大学 | 2022-03-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168717-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | COASY, NOTUM, MRPL21 | CA1 777/4885CA2 1098/4885CA7 1314/4885 |
| US-20240360062-A1 | HALOGENATED ETHER-CONTAINING ELECTROLYTES | SLC26A3, CLCN2, SLC26A4 | CA1 561/4885CA2 473/4885CA7 394/4885 |
| US-20240400559-A1 | SOLID STATE EMITTERS BASED ON PYRIDINIUM SCAFFOLDS | CYB5R3, NQO1, SQOR | CA1 4556/4885CA2 3559/4885CA7 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.